Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch Deutsch
CORDIS - Forschungsergebnisse der EU
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Future of ALCL: Novel Therapies, Origins, Bio-Markers and Mechanism of resistance

Projektbeschreibung

Bessere Behandlungsmöglichkeiten für ein seltenes Non-Hodgkin-Lymphom

Das anaplastisch-großzellige Lymphom ist ein seltenes Non-Hodgkin-Lymphom, das in allen Altersgruppen vorkommt, wobei jedoch Kinder und junge Erwachsene häufiger betroffen sind. Es kann sich als systemische oder lokal begrenzte Krankheit mit Symptomen wie geschwollenen Lymphknoten, Fieber, Müdigkeit und Gewichtsverlust manifestieren. Zu den Behandlungsoptionen zählen Chemotherapie, Strahlentherapie und Stammzelltransplantation. Das im Rahmen der Marie-Skłodowska-Curie-Maßnahmen unterstützte Projekt FANTOM zielt darauf ab, Forschende auf dem Gebiet des anaplastisch-großzelligen Lymphoms weiterzubilden, indem innovative Modellsysteme und Multi-Omik-Technologien zum Einsatz kommen. Untersucht wird die Rolle des Immunsystems und des Tumorstromas, um nichtinvasive Biomarker sowie neuartige therapeutische Ansätze zu entwickeln. Dieses Projekt wird dazu beitragen, unser Verständnis des anaplastisch-großzelligen Lymphoms zu vertiefen und bessere Behandlungsmöglichkeiten für die Betroffenen zu erschließen.

Ziel

The FANTOM Doctoral Network (DN) composed of 7 beneficiaries and 12 associated partners in 5 EU countries, recruiting 10 researchers and will be embedded into an established international research programme: The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (ERIA) as well as a clinical network: The European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL). FANTOM will cosset and nurture the recruited researchers to become confident, competent, independent and well-connected European scientists with excellent career perspectives welcomed into these established networks. This will be achieved through a training programme conducted through research and complemented by a balanced programme of transferable skills designed with key input from both academic and industrial collaborators. The training of each fellow will be guided by an individual career development plan and supervised by a PhD committee with clearly allocated academic and industrial supervisors. The primary goal of the network is to train the recruited fellows by participation in an internationally competitive research programme and integrating them into the aforementioned networks. The research programme will address the clinical problems posed by Anaplastic Large Cell Lymphoma (ALCL) typified by aberrant ALK expression. Applying innovative model systems and multi-omics technologies, some performed to a single cell level, the biology of ALCL including the roles of the immune system and tumour stroma will be uncovered. These data will be applied to the development of (non-invasive) biomarkers and novel therapeutic approaches that will culminate in the design of clinical trials to address the issues of chemotherapy toxicity, over-treatment and drug resistance. The research and training activities will incorporate not only academic labs but also key research institutes, biotechnology companies, clinical trial bodies and Pharma to realise our research goals.

Koordinator

Masarykova univerzita
Netto-EU-Beitrag
€ 474 076,80
Adresse
Zerotinovo namesti 9
601 77 Brno
Tschechien

Auf der Karte ansehen

Region
Česko Jihovýchod Jihomoravský kraj
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
Keine Daten

Beteiligte (7)

Partner (14)